University of Illinois-Chicago Matthew Meriggioli

University of Illinois-Chicago scientist receives $530,480 to test immune system modulator for myasthenia gravis

posted on March 14, 2011 - 3:51pm
Update (June 10, 2013): In 2013, Matthew Meriggioli relocated from the University of Illinois to the Novartis Institutes for BioMedical Research in Cambridge, Mass. The laboratory work on GM-CSF has been completed, and Meriggioli and other investigators are looking at the possibility of starting the clinical trial at an alternative site.

New content is being added every day. Please check back again.